Why Inotek Pharmaceuticals Sank 23% in September

Shares of Inotek Pharmaceuticals , a small-cap biopharma with a focus on diseases of the eye, dropped more than 20% during the month of September.

What caused such a huge sell-off? See the presentation below for details.

The article Why Inotek Pharmaceuticals Sank 23% in September originally appeared on Fool.com.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.